GleamWall
中文EN

AIBT AIBOTICS THERAPIES, INC.

Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1763329 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY-100.0%
TTM net income YoY-3.2%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-241.3%
ROIC (approx.)—
Asset turnover0.00x

Leverage & solvency

Liabilities / assets937.3%
Debt / equity—
Current ratio0.05x
Interest coverage-9.75x

Cash quality & payout

Operating cash flow / net income0.17x
Accruals ratio-201.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-312024Q32024-09-30
Income statement
Revenue$0$0$0$0$0$2,183$0$0
Gross profit$0$0$0$0$0$2,183$0$0
SG&A expense$413,663$359,463$474,265$480,365$360,579$531,647$497,278$385,257
Operating income-$413,663-$359,463-$474,265-$480,365-$360,579-$529,464-$497,278-$385,257
Interest expense$46,917$58,642$60,555$11,154$70,070$61,933-$5,764$74,887
Pretax income-$536,968-$418,105-$608,284-$529,921-$486,149-$591,397-$491,514-$460,144
Income tax$0$0$0$0$0$0$0$0
Net income-$536,968-$418,105-$608,284-$529,921-$486,149-$591,397-$491,514-$460,144
EBITDA-$413,663-$359,463-$474,265-$480,365-$360,579-$529,215-$497,278-$385,257
EPS (diluted)————————
Balance sheet
Cash & equivalents$233,427$288,858$255,940$230,470$242,179$156,737$185,097$202,358
Inventory$40,525$40,525$0—————
Current assets$275,619$331,050$270,107$241,396$242,179$156,737$185,097$203,058
PP&E, net$0$0$0——$0$0$0
Intangibles———$775,547$943,431—$1.27M—
Total assets$549,592$771,233$874,673$1.02M$1.19M$1.26M$1.46M$1.64M
Current liabilities$5.15M$5.05M$4.79M$4.90M$5.39M$5.10M$4.85M$5.00M
Total liabilities$5.15M$5.05M$4.83M$4.90M$5.39M$5.10M$4.85M$5.00M
Shareholders' equity-$4.60M-$4.28M-$3.96M-$3.89M-$4.21M-$3.84M-$3.39M-$3.36M
Shares outstanding722.51M539.37M486.90M318.89M51.63M45.24M39.99M5.48M
Cash flow statement
Operating cash flow-$47,022-$36,258-$86,604-$178,718-$164,558-$28,360-$17,261-$77,547
Investing cash flow$0$0——$0$0—$0
Financing cash flow-$8,409$69,176$112,074$167,009$250,000$0$0$0
Depreciation & amortization$0$0$0$0$0$249$0$0
Stock-based compensation——————$0$0

Free plan shows the latest 8 periods; Pro shows all 34 🔒

· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.